# Indivior Pharmaceuticals Inc. (INDV) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $34.94, market value $4.1 billion.

## Valuation
- **P/E (trailing): 12.5×** (5-yr avg 135.2×, 3-yr avg 135.2×). Indivior Pharmaceuticals Inc. trades at 12.5× trailing earnings, well below its own five-year average of 135.2×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 7.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.1×**. Each dollar of revenue is priced at 3.1×.
- **EV / EBITDA: 9.9×**. Enterprise value is 9.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: -2.7%** (5-yr avg -0.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 8.0%**. The inverse of the P/E: 8.0% of the price is earned each year.

## Profitability
- **Gross margin: 82.2%**. Indivior Pharmaceuticals Inc. keeps 82.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 31.6%**. 31.6% of revenue is left after running the business, an exceptional level.
- **Net margin: 16.9%**. 16.9% of each dollar of sales reaches the bottom line.
- **Return on equity: -214.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: 29.6%**. Each dollar of assets produces 29.6% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 11.2%/yr). Revenue grew 4.3% over the last year.
- **EPS growth (1 yr): 3180.0%**. Earnings per share rose 3180.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 0.3×**. It would take 0.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 3.54**. A Z-score of 3.54 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Indivior Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 41.3%** (YTD -2.6%, 3-mo -7.1%). The shares are up 41.3% over twelve months including dividends.
- **From 52-week high: -18.4%** (57.2% above the low). Trading 18% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 33**. An RSI of 33 is neutral.
- **Beta (1 yr): 0.42** (volatility 37%). Beta of 0.42 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INDV · Page: https://foliofundamentals.com/stocks/indv

Not investment advice.